zamtocabtagene autoleucel

Phase 2Cell therapy

zamtocabtagene autoleucel is one of 63 biologic programs targeting Diffuse Large B-cell Lymphoma(DLBCL). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Large B-Cell Lymphoma(dlbcl)Recruiting

B-Cell NeoplasmRecruiting

Autoimmune DiseaseNot yet recruiting

Diffuse Large B-Cell Lymphoma(dlbcl)Phase 2

Recruiting

B-Cell NeoplasmPhase 2

Recruiting

Autoimmune DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

74 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 2

2 2

Cytosar

Teva

Phase 2

1 3

Rayos

RRoxane Laboratories

Phase 2

2 4

Alkeran

AApotex Inc.

Phase 2

1 5

Vepesid

AAvyxa

Phase 2

1 6

Bicnu

MMelissa K Accordino

Phase 2

1 7

Fludara

Sanofi

Phase 1

8 8

CAR-T Cell

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

3 9

Anti-CD19 CAR-T Cells

TThe Children's Hospital of Zhejiang University School of Medicine

Phase 2

2 10

CD19 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Autoimmune Disease

NCT06708845

Q4 2028

Phase 2Recruiting

Diffuse Large B-Cell Lymphoma(dlbcl)

NCT04792489

Q4 2029

Phase 2Recruiting

B-Cell Neoplasm

NCT06508931

Clinical

Trials by Indication[1]

B-cell neoplasm1 trial

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Recruiting·MMiltenyi Biomedicine GmbH·Phase 2·NCT06508931·31 enrolled

Autoimmune Disease1 trial

US Zamto-cel Autoimmune Diseases

Not yet recruiting·MMiltenyi Biomedicine GmbH·Phase 1·NCT06708845·48 enrolled

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Recruiting·MMiltenyi Biomedicine GmbH·Phase 2·NCT04792489·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for zamtocabtagene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zamtocabtagene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zamtocabtagene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Miltenyi Biomedicine GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MMiltenyi Biomedicine GmbH

zamtocabtagene autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q4 2029

Trials by Indication[1]

B-cell neoplasm1 trial

Autoimmune Disease1 trial

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

References

Drug Info

Quick Facts

Related News